Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD-iEXo-002 Nasal Drops for Refractory Focal Epilepsy
NCT05886205Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Lipid-based Nanoparticles, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iPSC-derived exosomes in Focal Epilepsy (FE), sponsored by Peking Union Medical College Hospital. Primary endpoint: Adverse Events at 24 weeks. Status: unknown.
02
Drugs
iPSC-derived exosomes
03
Conditions
Focal Epilepsy (FE)
Beyond the preview
Go deeper on NCT05886205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886205.